Your browser doesn't support javascript.
loading
Intermediate-risk endometrial cancer treated with adjuvant brachytherapy using single dosimetric planning: long-term outcome and toxicity assessment.
Cordoba, Abel; El Hajj, Houssein; Escande, Alexandre; Scouarnec, Cyrielle; Narducci, Fabrice; Martinez Gomez, Carlos; Leblanc, Eric; Hudry, Delphine; Pasquesoone, Camille; Taieb, Sophie; Mirabel, Xavier; Lartigau, Eric F; Le Tinier, Florence.
Afiliação
  • Cordoba A; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France. Electronic address: a-cordoba@o-lambret.fr.
  • El Hajj H; Department of Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.
  • Escande A; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France.
  • Scouarnec C; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France.
  • Narducci F; Department of Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.
  • Martinez Gomez C; Department of Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.
  • Leblanc E; Department of Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.
  • Hudry D; Department of Surgical Oncology, Oscar Lambret Cancer Centre, Lille, France.
  • Pasquesoone C; Department of Pathology, Oscar Lambret Cancer Centre, Lille, France.
  • Taieb S; Department of Medical Imaging, Oscar Lambret Cancer Centre, Lille, France.
  • Mirabel X; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France.
  • Lartigau EF; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France.
  • Le Tinier F; Academic Department of Radiation Oncology and Brachytherapy, Oscar Lambret Cancer Centre, Lille, France.
Eur J Obstet Gynecol Reprod Biol ; 298: 23-30, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38705010
ABSTRACT

OBJECTIVE:

Brachytherapy of the vaginal dome is the recommended adjuvant treatment for intermediate-risk endometrial cancer. This study assessed the results of dosimetric planning of high-dose-rate brachytherapy exclusively in the first treatment session. STUDY

DESIGN:

This retrospective study included all patients who underwent hysterectomy for endometrial cancer followed by adjuvant brachytherapy of the vaginal dome between 2012 and 2015. Local recurrence rates, overall survival (OS) rates, recurrence-free survival (RFS) rates, and related acute and late toxicity rates were evaluated.

RESULTS:

This analysis included 250 patients, of whom 208 were considered to be at high-intermediate risk of disease recurrence. After a median follow-up of 56 months, the cumulative incidence of local recurrence was 4.8% at 3 years [95% confidence interval (CI) 2.8-8.3] and 7.8% at 5 years (95% CI 4.8-12.6). The 5-year OS rate was 86.2% (95% CI 80.6-90.3), and the 5-year RFS rate was 77.5% (95% CI 71.1-82.7). Acute toxicity occurred in 20 (8%) patients, of which two patients had grade ≥3 toxicity. Only one patient (0.4%) presented with late grade ≥3 toxicity.

CONCLUSION:

These findings confirm the tolerability of this brachytherapy approach, indicating minimal cases of late grade ≥3 toxicity, associated with a good 5-year OS rate. With the advent of molecular prognostic factors, the current focus revolves around discerning those individuals who gain the greatest benefit from adjuvant therapy, and tailoring treatment more effectively.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Endométrio Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Eur J Obstet Gynecol Reprod Biol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Braquiterapia / Neoplasias do Endométrio Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Eur J Obstet Gynecol Reprod Biol Ano de publicação: 2024 Tipo de documento: Article